Discover the Artistic Journey of Madonna's Family
Starting with Lola
Lola, Madonna's eldest child, is a true prodigy. Not only was she an exceptional ballet dancer and rhythmic gymnast, but she also seamlessly transitioned to musical theater and contemporary dance. Now, she has emerged as a unique singer and songwriter in her own right. When Madonna goes on tour, there is nothing that brings her more joy than knowing that they are all working together on the same show, creating magic.Lola's talent and dedication have allowed her to carve out a distinct path in the world of art. Her ability to excel in multiple disciplines is a testament to her creativity and hard work.
Madonna's pride in Lola's achievements is evident as she shares these stories with her fans. It shows the power of nurturing artistic talents from a young age.
David's Musical Journey
David has been playing guitar since he was a child. His love for music has been a constant in his life, and it has led him to develop a unique musical style. Madonna's support for his artistic endeavors has played a significant role in his growth.Playing the guitar is not just a hobby for David; it is a part of his identity. His passion for music shines through in every note he plays.
Madonna's encouragement has given David the confidence to pursue his dreams and share his music with the world. It is a beautiful example of how a parent can inspire their child's artistic growth.
Mercy's Classical Training
Mercy started playing the piano at the age of 8 and has been classically trained for most of her life. Her piano skills are exceptional, and she has a deep understanding of classical music.Mercy's dedication to classical music is remarkable. Her ability to master complex pieces is a testament to her talent and perseverance.
Classical training has given Mercy a solid foundation in music, and it has opened up many opportunities for her. Madonna is proud of Mercy's achievements and is happy to see her pursue her passion.
The Twins' Musical and Dance Beginnings
When Madonna adopted the twins, they started to play piano and dance. Their natural inclination towards these arts was evident from the start.The twins' enthusiasm for music and dance is infectious. They have quickly become a part of the family's artistic legacy.
Madonna's role in nurturing their talents has been crucial. She has provided them with the support and guidance they need to grow as artists.
Stella's Artistic Expression
Stella was the shyest among the children, but she comes alive on stage. She is an incredible fine artist, with a unique vision and talent.Stella's shyness hides a vibrant artistic spirit. When she steps onto the stage, she transforms into a confident artist.
Following in the footsteps of Rocco, who has also found his artistic niche as a painter, Stella is showing great promise. Madonna is hopeful that she will continue to pursue her artistic dreams.
Congress Pushes for Clarity on HHS' AI Assurance Lab Plans
Background and Concerns
With deregulation a priority for the incoming Trump Administration in 2025, Republicans have been closely monitoring how AI in healthcare will be regulated. In their letter to Micky Tripathi, who also serves as Assistant Secretary for Technology Policy Secretary and National Coordinator for Health IT, the representatives raised questions about the overarching objectives of the agency's reorganization and the potential for conflict of interest.
Part of a larger technology restructuring effort by HHS, the new ASTP - formerly Office of the National Coordinator for Health Information Technology - announced in July that it would have increased responsibilities, including over healthcare AI. However, the representatives believe that the creation of assurance labs could supplement the U.S. Food & Drug Administration's review of AI tools and lead to significant issues.
Specific Concerns about Assurance Labs
The representatives are particularly troubled by the possible creation of fee-based assurance labs that would be comprised of competing companies. They fear that larger, incumbent tech companies could gain an unfair competitive advantage and negatively impact innovation in the industry. This concern was highlighted when Miller-Meeks specifically asked if the FDA would outsource certification to the coalition, noting that Google and Microsoft are founding members while Mayo Clinic, which has more than 200 AI deployments, employs some of the coalition's leaders.
"It does not pass the smell test," she said, suggesting clear signs of an attempt at regulatory capture. CHAI, which unveiled standards for healthcare AI transparency, has said a long-awaited AI nutrition label will be coming soon. Dr. John Halamka, president of Mayo Clinic Platform, addressed the substantial potential benefits and real potential harms that could come from predictive and generative AI used in clinical settings earlier this year at HIMSS24.
"Mayo has an assurance lab, and we test commercial algorithms and self-developed algorithms," he said in March. "And what you do is you identify the bias and then you mitigate it. It can be mitigated by returning the algorithm to different kinds of data, or just an understanding that the algorithm can't be completely fair for all patients. You just have to be exceedingly careful where and how you use it."
Call for Responses and Ongoing Dialogue
The representatives included eleven questions and requested responses by December 20. A spokesperson for ASTP told Healthcare IT News by email that the agency is unable to comment on the letter at this time. CHAI has not responded to our request for comment, but this story will be updated if one is provided.
"The ongoing dialogue around AI in healthcare must consider the distinct authorities and duties of various agencies and offices to prevent overlapping responsibilities, which can lead to confusion among regulated entities," the four Republican members of Congress said in their letter. This highlights the importance of a clear and coordinated approach to AI regulation in healthcare.
Humana's Financial Leadership Transition
Diamond's Departure and Her Impact
Susan Diamond's decision to leave Humana after 18 years is a significant event. She has played a crucial role in the company's financial management during a challenging period. Her expertise and leadership have been instrumental in navigating the insurer through various financial situations. With her departure, Humana now faces the task of finding a suitable replacement to continue driving the company's financial success.During her tenure, Diamond has overseen important financial decisions and strategies that have shaped Humana's financial position. Her departure will leave a void that needs to be filled by a capable individual who can understand the intricacies of the healthcare industry and the insurer's financial operations.
Mellet's Appointment and Her Qualifications
Celeste Mellet, the chosen successor to Diamond, brings a wealth of experience to Humana. She comes from Global Infrastructure Partners and has previously worked at investment banks Evercore and Morgan Stanley, as well as mortgage financier Fannie Mae.Humana CEO Jim Rechtin praised Mellet, stating that she is a highly accomplished CFO with first-hand experience navigating dynamic and highly regulated industries. Her proven track record of working with cross-functional teams makes her well-suited to drive improved performance throughout the complex organization.
Financial Turmoil at Humana
Humana has been facing financial turmoil in recent months. In April, the company pulled its profit outlook for 2025 due to declining payment rates in Medicare Advantage. Payers in the privatized Medicare program are managing increased medical spending among beneficiaries, which has put pressure on Humana's finances.The insurer is also facing a significant drop in MA star ratings for next year, which could have a substantial impact on its financial performance. In late October, Humana sued the HHS over its star ratings, arguing that federal regulators calculated the scores in an arbitrary and capricious manner.
Progress in Improving Financial Position
Despite the challenges, Humana has made some progress in improving its financial position in the third quarter. The company posted better results than analysts anticipated and boosted its 2025 earnings guidance.On Tuesday, Humana reiterated its adjusted profit guidance for this year, expecting at least $16 per share. The insurer also expects adjusted profit for 2025 to be "at least in line with final 2024 results." These positive developments give hope for the company's future financial performance.